GLG News by Breast Oncologists in Private Practice (US)

Tomotherapy may do well after all with newer bells and whistles introduced at ASTRO 2008. Protons are likely to die leaving investors with a huge bill and dwindling ROI. Short course breast radiotherapy is not worth the risk.

New data with low and high dose of Avastin with Taxoter

esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...

“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never...

This article reports on Varian's answer to Tomotherapy which has been gaining some market share in the Radiation Oncology linear accelerator arena. Tomotherapy has a good product but requires a shift in treatment planning technique and complete replacement of hardware. There have been reports about...

CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation

The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate

The coverage restrictions placed on the FDA-approved indication have no scientific basis and are incompatible with good clinical practice," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Global Research and Development at Amgen. "We are concerned that inappropriately limiting coverage...

My understading id medicare need to cover all FDA indicated drugs. Here CMS violating FDA indication for Aranesp and procrit

Decrease use by 20-25% use of ESA. This may lead discounting and higher rebate from both amgen and orto-biotech to sustain market share. Since most of amgen contract with aranesp and neulasta use. It may effect use of neulasta. Next 6 month CMS may restrict use of Neulasta and neupogen for neutropenia...